Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19
Partner

Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19

Sponsored by Stanford University


The objective of this study is to evaluate the efficacy of oral favipiravir plus standard of care treatment (SOC) compared with placebo plus SOC in reducing the duration of shedding of SARS-CoV2 virus in patients with mild or asymptomatic COVID-19.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study Type: Interventional (Clinical Trial) Estimated Enrollment: 120 participants Primary Purpose: Treatment Estimated Study Start Date: July 2020 Estimated Study Completion Date: July 2021

Who is this study for?

  • Age 18-80
  • Have a positive COVID-19/SARS-CoV-2 test in the last 2 days
  • Are not currently hospitalized
  • Ability to return to Stanford campus for follow-up visits

What should I expect?

Experimental: Favipiravir In addition to SOC, participants will receive favipiravir for 10 days, and be evaluated for health outcomes through day 28.

Active Comparator: Placebo In addition to SOC, participants will receive placebo to match favipiravir for 10 days, and be evaluated for health outcomes through day 28.

Have questions or need help?

For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.